Detalhe da pesquisa
1.
Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Lancet
; 402(10401): 555-570, 2023 08 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37423231
2.
Active lupus in Argentina: Results of a multicenter and national registry.
Lupus
; 32(13): 1555-1560, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37936393
3.
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.
Lancet
; 398(10315): 1984-1996, 2021 11 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767764
4.
Multicenter lupus register from Argentina, the RELESSAR database: Influence of ethnicity on disease phenotype.
Lupus
; 31(5): 637-645, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35382633
5.
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
Rheumatology (Oxford)
; 60(10): 4495-4507, 2021 10 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493312
6.
Efficacy, Safety, and Immunogenicity of Biosimilar Etanercept (Enerceptan) Versus Its Original Form in Combination With Methotrexate in Patients With Rheumatoid Arthritis: A Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study.
J Clin Rheumatol
; 27(6S): S173-S179, 2021 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33337815
7.
Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study.
Clin Exp Rheumatol
; 38(4): 732-741, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452344
8.
Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.
Rheumatology (Oxford)
; 58(5): 849-858, 2019 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30590833
9.
Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes.
Rheumatology (Oxford)
; 57(8): 1423-1431, 2018 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29746672
10.
Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial.
Ann Rheum Dis
; 76(3): 534-542, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27672124
11.
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Ann Rheum Dis
; 74(6): 1110-7, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24834925
12.
Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.
Arthritis Rheum
; 65(9): 2368-79, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23740801
13.
Sifalimumab, a human anti-interferon-α monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study.
Arthritis Rheum
; 65(4): 1011-21, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23400715
14.
Rheumatoid arthritis in Latin Americans enriched for Amerindian ancestry is associated with loci in chromosomes 1, 12, and 13, and the HLA class II region.
Arthritis Rheum
; 65(6): 1457-67, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23460240
15.
Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina.
J Clin Rheumatol
; 19(8): 439-43, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24263146
16.
[Prevalence of dyslipidemia and elevated cardiovascular risk in patients with rheumatoid arthritis]. / Prevalencia de dislipemia y riesgo cardiovascular elevado en pacientes con artritis reumatoide.
Medicina (B Aires)
; 73(1): 26-30, 2013.
Artigo
em Espanhol
| MEDLINE | ID: mdl-23335702
17.
General characteristics of an early arthritis cohort in Argentina.
Rheumatology (Oxford)
; 50(1): 110-6, 2011 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20663815
18.
Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study.
J Rheumatol
; 48(7): 969-976, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33323529
19.
Safety and Efficacy of Filgotinib: Up to 4-year Results From an Open-label Extension Study of Phase II Rheumatoid Arthritis Programs.
J Rheumatol
; 48(8): 1230-1238, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33526618
20.
Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study.
Ther Adv Musculoskelet Dis
; 13: 1759720X211006964, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33959198